Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Novel Therapeutic Strategy Targeting Photoreceptor Oxidative Damage in ABCR-related Retinal Degenerations

NCT01278277 is registered in ClinicalTrials.gov with Catholic University of the Sacred Heart as lead sponsor.

NCT NCT01278277
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01278277 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Novel Therapeutic Strategy Targeting Photoreceptor Oxidative Damage in ABCR-related Retinal Degenerations
Lead sponsor
Catholic University of the Sacred Heart
Phase
Phase 1/2
Overall status
Unknown status
Start date
February 28, 2011
Completion date
December 31, 2017
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

genetic disease, macular dystrophy, retinal degeneration, single-gene defects